BELLUS Health Inc. (NASDAQ:BLU – Get Rating) fell 10.9% on Thursday . The company traded as low as $7.09 and last traded at $7.10. 7,215 shares traded hands during mid-day trading, a decline of 99% from the average session volume of 916,343 shares. The stock had previously closed at $7.97.
Separately, HC Wainwright upped their target price on BELLUS Health from $14.00 to $16.00 and gave the stock a “buy” rating in a research note on Thursday, February 24th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, BELLUS Health has a consensus rating of “Buy” and an average price target of $16.25.
The firm has a market cap of $820.89 million, a PE ratio of -8.69 and a beta of 0.19. The firm has a fifty day simple moving average of $8.15 and a two-hundred day simple moving average of $7.18.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Toronto Dominion Bank grew its stake in BELLUS Health by 35,900.0% in the 1st quarter. Toronto Dominion Bank now owns 3,600 shares of the company’s stock valued at $25,000 after acquiring an additional 3,590 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of BELLUS Health in the 1st quarter worth approximately $27,000. Royal Bank of Canada grew its stake in shares of BELLUS Health by 66.2% in the third quarter. Royal Bank of Canada now owns 10,861 shares of the company’s stock valued at $67,000 after buying an additional 4,327 shares in the last quarter. ProShare Advisors LLC purchased a new stake in BELLUS Health during the fourth quarter worth about $89,000. Finally, Cibc World Market Inc. purchased a new position in BELLUS Health in the 1st quarter valued at approximately $98,000. 85.41% of the stock is currently owned by institutional investors.
BELLUS Health Company Profile (NASDAQ:BLU)
BELLUS Health Inc, a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus.
- Get a free copy of the StockNews.com research report on BELLUS Health (BLU)
- The Q2 Earnings Season Could Be A Bloodbath
- Commercial Metals Company Is Ready To Rebound
- The Institutions Turn The Tide For Jabil
- A10 Networks: Key 5G Infrastructure Stock that’s Beating the Market
- Allstate: A Safe Stock During Volatile Times, Which Will Benefit From Rising Rates
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for BELLUS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BELLUS Health and related companies with MarketBeat.com's FREE daily email newsletter.